(Q26765488)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

28 October 2022

New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

main subject

acute coronary syndrome

2 references

28 October 2022

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Mariano Valdés Chávarri

series ordinal

3

object named as

Mariano Valdés

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

María Asunción Esteve-Pastor

9 March 2020

series ordinal

1

object named as

María Asunción Esteve-Pastor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Diana Hernández-Romero

series ordinal

2

object named as

Diana Hernández-Romero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

27 February 2016

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

28 October 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

9 March 2020

copyright license

1 reference

28 October 2022

Bivalirudin for acute coronary syndromes: premises, promises and doubts.

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Progress in the design of low molecular weight thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

What is all that thrombin for?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Factor Xa or thrombin: is factor Xa a better target?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Triggers, targets and treatments for thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Coronary plaque disruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Molecular and cellular biology of blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Factor VIIa-mediated tenase function on activated platelets under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Thrombin domains: structure, function and interaction with platelet receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Platelet thrombin receptor antagonism and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Thrombin signalling and protease-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Platelets and thrombin generation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

An overview of the structure and function of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Anticoagulant therapy for percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Promise of factor Xa inhibition in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Past, present and future of hirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Kinetic mechanism for the interaction of Hirulog with thrombin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Bivalirudin: a direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Bivalirudin started during emergency transport for primary PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration w

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribu

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention. A meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

The mechanism of action of thrombin inhibitors

21 January 2018

1 reference

12 December 2020

Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention.

1 reference

12 December 2020

Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass

1 reference

12 December 2020

Thrombin-specific inhibition by and slow cleavage of hirulog-1

1 reference

12 December 2020

A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial

1 reference

12 December 2020

Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial

1 reference

12 December 2020

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

12 December 2020

Prognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Non–ST-Segment Elevation Myocardial Infarction Patients

1 reference

12 December 2020

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

1 reference

12 December 2020

Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease

1 reference

12 December 2020

Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events

1 reference

12 December 2020

Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome

1 reference

12 December 2020

Bivalirudin Versus Heparin: A Fight Far From Finished?: Efficacy, Safety, and Cost Remain Battlegrounds for the Treatment Of ST-Segment Elevation Myocardial Infarction

1 reference

12 December 2020

'Realworld' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry

1 reference

12 December 2020

Bivalirudin versus heparin in patients with acute myocardial infarction: A meta-analysis of randomized trials

1 reference

12 December 2020

Effect of shear stress on clot structure formation

1 reference

12 December 2020

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

12 December 2020

Plasmin-mediated activation of contact system in response to pharmacological thrombolysis

1 reference

12 December 2020

The influence of fibrinogen and fibrin on thrombin generation--evidence for feedback activation of the clotting system by clot bound thrombin

1 reference

12 December 2020

Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects

1 reference

12 December 2020

Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans

1 reference

12 December 2020

Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty

1 reference

12 December 2020

Plaque rupture, thrombosis, and therapeutic implications

1 reference

12 December 2020

On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B

1 reference

12 December 2020

Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.

1 reference

12 December 2020

Thrombin and antithrombotics

1 reference

12 December 2020

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

12 December 2020

Are we mortgaging the medical profession?

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

7 January 2021

inferred from DOI database lookup

CardioPulse: 'Ten Commandments' of 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS)

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21030284

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.3390/MOLECULES21030284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26927051%20AND%20SRC:MED&resulttype=core&format=json